Nyu op fɔ di wan dɛn we gɛt Alzaima? Lɛ wi tɔk bɔt dis nyu mɛrɛsin (Donanemab).

If sɔmbɔdi na yu famili, sɔntɛm yu mama, papa, ɔ grani we yu lɛk, gɛt wan sik we dɛn kɔl Alzaima, wi no aw i kin mek yu fil pen. I kin rili sɔri fɔ si di pɔsin we yu lɛk in mɛmori nɔ de igen smɔl smɔl. Bɔt, insay dis tranga tin, wi de tɔk bɔt wan nyus we de briŋ smɔl op. Dis nɔto kɔmplit mɛrɛsin fɔ di sik, bɔt i kin bi impɔtant step fɔ go bifo.

Wetin na dis nyu nyus?

I nɔ tu te yet, wan advayz panɛl na di US Food and Drug Administration (FDA) bin gri fɔ gi grɛn layt fɔ wan nyu tritmɛnt fɔ Alzaima. Di nem fɔ di mɛrɛsin na donanemab . I fayn fɔ di wan dɛn we sik we di sik bigin . Di aprɔval fɔ dis advayz panɛl min se chans de fɔ mek di FDA gi ful aprɔval to dis drɔg jisnɔ. Dis na rili big tin, bikɔs di kam fɔ nyu tritmɛnt fɔ wan siriɔs sik lɛk Alzaima na big op.

Aw Donanemab de wok?

Okay, naw mek wi si aw dis drɔg de wok. Dis na tin we kɔmplikt smɔl, bɔt a go ɛksplen am simpul wan. Donanemab na wan kayn mɛrɛsin we dɛn kɔl monoklɔnal antibodi . Fɔ tɔk am simpul wan, na spɛshal protin we dɛn mek na di lab fɔ atak wan patikyula target we de yuz pat dɛn pan wi yon imyun sistɛm. Wetin na di target fɔ dis drɔg? Na amyloid plaques , wae dɛn kin tink se na wan big tin wae kin mek pɔrsin gɛt Alzaima sik. Jɔs lɛk aw rɔst kin gɛda na wi wata paip dɛn, dɛn plek ya kin gɛda bitwin di nɛv sɛl dɛn na di bren ɛn ambɔg dɛn wok. Wetin Donanemab de du na fɔ no dɛn plek ya ɛn ɛp fɔ pul dɛn.

Aw dis mɛrɛsin de wok?

Frɔm di rizɔlt fɔ di klinik trial dɛm we dɛn bin pul las ia, dis tritmɛnt kin slo di rit we di sik kin wɔs insay sɔm mɔnt.I dɔn pɔsibul. Dɛn kin mɛzhɔ dis tru tɛst dɛm we de mɛzhɔ di sikman dɛn intɛlektual abiliti (e.g., mɛmori, sɔlv prɔblɛm) ɛn aw dɛn de du fayn fayn wok dɛm fɔ liv ɛvride (e.g., fɔ drayv, fɔ manej mɔni). Sɔm masta sabi pipul dɛn kin kɔl dɛn rizɔlt ya mɔdest ɔ "nɔmal" rizɔlt. Dat min se yu nɔ go ebul fɔ ɛkspɛkt big difrɛns frɔm dis. Bɔt i fayn bak fɔ mek di sik slo insay jɔs sɔm mɔnt, pas fɔ mek i wɔs if yu nɔr gɛt ɛni tritmɛnt. As fɔ di we aw dɛn de gi di tritmɛnt, dɛn kin gi di mɛrɛsin to di sik pipul dɛn ɛvri mɔnt tru wan vein (infusion). Dɛn dɔn gi di wan dɛn we tek pat pan di trayal dɛn dis tritmɛnt fɔ lɛk wan ɛn af ia so.

Benefit dɛn de ɛn siriɔs risk dɛn de bak.

Lɛk ɛni pawaful mɛrɛsin, donanemab gɛt bɛnifit ɛn i gɛt siriɔs sayd ɛfɛkt ɛn risk. I impɔtant fɔ ɔndastand ɔl tu di say dɛn bifo yu disayd fɔ du sɔntin. Pan ɔl dɛn tin ya we dɛn bin de tink bɔt, di FDA advayz panɛl bin dɔn disayd se di bɛnifit dɛn we dis mɛrɛsin gɛt pas di prɔblɛm dɛn we i gɛt.Dat min se if dɛn gi am to di rayt pasɛnt dɛn, ɔnda di rayt sɔpɔtishɔn, di bɛnifit dɛn go bɔku.

Dis na di wangren nyu mɛrɛsin we de?

Nɔ, ɔda mɛrɛsin de we de wok di sem we. Dɛn kɔl am lekanemab . Da drɔg de wok bak bay we i de tɔch di pletlɛt dɛn we de gɛda na di bren. I bin gɛt FDA aprɔval insay Julay 2023. Donanemab na ɔda step na da joyn de. De big big Alzaima asosieshɔn dɛm na di wɔl gɛt bɔrku op fɔ nyu tritmɛnt dɛm lɛk dis. Dɛn se, "Di mɔ tritmɛnt dɛn we dɛn dɔn gri fɔ lɛk dis de kɔmɔt, na di mɔ di chans fɔ mek di sik pipul dɛn kwalifay fɔ dɛn. Dɛn de mek klia prɔgrɛs pan tritmɛnt." Naw, bɔku bɔku pipul dɛn ɔlsay na di wɔl gɛt wan sik we dɛn kɔl Alzaima. No we stil nɔ de fɔ mek dɛn nɔ gɛt dis sik ɔltogɛda ɔ mɛn am. So, drɔgs lɛk donanemab na rili impɔtant maylston dɛn na da lɔng waka de. Alzaima sik, donanemab, bren sik, mɛmori lɔs, dimɛns, nyu tritmɛnt, monoklɔnal antibodi